Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar 16:2:46.
doi: 10.3389/fmicb.2011.00046. eCollection 2011.

Oncolytic bluetongue viruses: promise, progress, and perspectives

Joseph K-K Li  1
Affiliations

Oncolytic bluetongue viruses: promise, progress, and perspectives

Joseph K-K Li. Front Microbiol. .

Abstract

Humans are sero-negative toward bluetongue viruses (BTVs) since BTVs do not infect normal human cells. Infection and selective degradation of several human cancer cell lines but not normal ones by five US BTV serotypes have been investigated. We determined the susceptibilities of many normal and human cancer cells to BTV infections and made comparative kinetic analyses of their cytopathic effects, survival rates, ultra-structural changes, cellular apoptosis and necrosis, cell cycle arrest, cytokine profiles, viral genome, mRNAs, and progeny titers. The wild-type US BTVs, without any genetic modifications, could preferentially infect and degrade several types of human cancer cells but not normal cells. Their selective and preferential BTV-degradation of human cancer cells is viral dose-dependent, leading to effective viral replication, and induced apoptosis. Xenograft tumors in mice were substantially reduced by a single intratumoral BTV injection in initial in vivo experiments. Thus, wild-type BTVs, without genetic modifications, have oncolytic potentials. They represent an attractive, next generation of oncolytic viral approach for potential human cancer therapy combined with current anti-cancer agents and irradiation.

Keywords: cancer treatment; oncolytic bluetongue viruses; selective cytotoxic effects; viratherapeutics.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Aghi M., Martuza R. L. (2005). Oncolytic viral therapies – the clinical experience. Oncogene 24, 7802–781610.1038/sj.onc.1209037 - DOI - PubMed
    1. Alain T., Kim M., Johnston R. N., Urbanski S., Kossakowska A. E., Forsyth P. A., Lee P. W. K. (2006). Translational therapeutics. Br. J. Cancer 95, 1020–102710.1038/sj.bjc.6603363 - DOI - PMC - PubMed
    1. Alain T., Kim T. S. Y., Lun X., Liacini A., Schiff L. A., Senger D. L., Forsyth P. A. (2007). Proteolytic disassembly is a critical determinant for reovirus oncolysis. Mol. Ther. 15, 1512–1521 - PMC - PubMed
    1. Bansal O. B., Stokes A., Bansal A., Bishop D., Roy P. (1998). Membrane organization of bluetongue virus nonstructural glycoprotein NS3. J. Virol. 72, 3362–3369 - PMC - PubMed
    1. Barber T. L., Jochim M. M., Osburn B. I. (1985). Bluetongue and related orbiviruses. Prog. Clin. Biol. Res. 178, 746–750

LinkOut - more resources